Marshall Wace LLP Has $36.45 Million Position in Denali Therapeutics Inc. (NASDAQ:DNLI)

Marshall Wace LLP trimmed its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 9.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,788,737 shares of the company's stock after selling 178,404 shares during the period. Marshall Wace LLP owned about 1.24% of Denali Therapeutics worth $36,454,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in Denali Therapeutics by 7.6% during the 4th quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company's stock valued at $244,993,000 after purchasing an additional 843,996 shares during the period. FMR LLC increased its holdings in shares of Denali Therapeutics by 2.4% in the 4th quarter. FMR LLC now owns 8,019,746 shares of the company's stock valued at $163,442,000 after purchasing an additional 188,368 shares during the period. Alliancebernstein L.P. boosted its holdings in shares of Denali Therapeutics by 8.8% during the fourth quarter. Alliancebernstein L.P. now owns 3,315,642 shares of the company's stock worth $67,573,000 after purchasing an additional 268,378 shares during the period. Principal Financial Group Inc. grew its position in Denali Therapeutics by 13.8% during the third quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company's stock valued at $36,076,000 after purchasing an additional 149,939 shares in the last quarter. Finally, Norges Bank acquired a new position in Denali Therapeutics in the 4th quarter valued at approximately $21,717,000. Institutional investors and hedge funds own 92.92% of the company's stock.

Denali Therapeutics Stock Up 3.7 %

NASDAQ:DNLI traded up $0.56 during trading hours on Thursday, hitting $15.43. 609,172 shares of the stock were exchanged, compared to its average volume of 1,075,291. The company has a market capitalization of $2.24 billion, a P/E ratio of -5.60 and a beta of 1.58. The company's 50 day moving average is $15.21 and its two-hundred day moving average is $21.02. Denali Therapeutics Inc. has a twelve month low of $10.57 and a twelve month high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.08. On average, equities research analysts expect that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Analyst Ratings Changes

DNLI has been the topic of several research analyst reports. Oppenheimer lowered their price target on shares of Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating on the stock in a report on Monday, March 3rd. B. Riley restated a "buy" rating and issued a $35.00 target price (down previously from $38.00) on shares of Denali Therapeutics in a research note on Wednesday, March 5th. HC Wainwright upped their target price on Denali Therapeutics from $80.00 to $87.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Bank of America lowered their target price on shares of Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating on the stock in a research report on Monday, March 10th. Finally, William Blair reaffirmed an "outperform" rating on shares of Denali Therapeutics in a research report on Friday, February 28th. One investment analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $37.57.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.